Trend Results : Anderson Cancer Center


Blog Post Results (1-20 of 466)

FILTER RESULTS

MD Anderson receives $22 million in CPRIT funding for research, prevention and recruitment

(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center was awarded $22.3 million from the Cancer Prevention and Research Institute of Texas (CPRIT), accounting for 30 percent of the $73.5 million in awards CPRIT announced today.

Kinase inhibitor larotrectinib shows durable anti-tumor abilities in patients of all ages with 17 un

(University of Texas M. D. Anderson Cancer Center) Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses. Show More Summary

Obesity associated with longer survival for men with metastatic melanoma

(University of Texas M. D. Anderson Cancer Center) Obese patients with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal body mass index (BMI), investigators report...Show More Summary

Smart bomb virus shows promise as brain tumor immunotherapy

(University of Texas M. D. Anderson Cancer Center) A common cold virus engineered to attack the most common and deadly of brain tumors allowed 20 percent of patients with recurrent glioblastoma to live for three years or longer, researchers from The University of Texas MD Anderson Cancer Center report on a phase I clinical trial in the Journal of Clinical Oncology.

Stand Up To Cancer awards 2018 Laura Ziskin Prize in Translational Research

(Entertainment Industry Foundation) SU2C awarded the $250,000 2018 Laura Ziskin Prize in Translational Research to Drs. Jos Jonkers of the Netherlands Cancer Institute and Helen Piwnica-Worms of the MD Anderson Cancer Center to examine...Show More Summary

MD Anderson study evaluates need for biopsies during follow-up care in women with early breast cancer

(University of Texas M. D. Anderson Cancer Center) In an analysis of more than 120,000 women diagnosed with and treated for early-stage breast cancer, researchers from The University of Texas MD Anderson Cancer Center determined the rate of additional breast biopsies needed for these patients during their follow-up care. Show More Summary

MD Anderson Study Evaluates Need for Biopsies During Follow-Up Care in Women with Early Breast Cancer

In an analysis of more than 120,000 women diagnosed with and treated for early-stage breast cancer, researchers from The University of Texas MD Anderson Cancer Center determined the rate of additional breast biopsies needed for these...Show More Summary

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

(University of Texas M. D. Anderson Cancer Center) A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at The University of Texas MD Anderson Cancer Center report in Lancet Oncology. Show More Summary

National Academy of Sciences awards Kovalenko medal to immunotherapy pioneer Allison

(University of Texas M. D. Anderson Cancer Center) Cancer immunotherapy innovator Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive the 2018 Jessie Stevenson Kovalenko Medal for outstanding research in medical sciences, the National Academy of Sciences announced today.

National Academy of Sciences Awards Kovalenko Medal to Immunotherapy Pioneer Allison

Cancer immunotherapy innovator Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive the 2018 Jessie Stevenson Kovalenko Medal for outstanding research in medical sciences, the National Academy of Sciences announced today.

New cancer model shows genomic link between early-stage and invasive breast cancer types

(University of Texas M. D. Anderson Cancer Center) A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to a more invasive form of cancer say researchers at The University of Texas MD Anderson Cancer Center.

Small-cell lung cancer patients face barriers to receiving standard-of-care treatment

(University of Texas M. D. Anderson Cancer Center) Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the initial management of non-metastatic small-cell lung cancer (SCLC),...Show More Summary

AML study reports high response rates with combination targeted therapy

(University of Texas M. D. Anderson Cancer Center) Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers at The University of Texas MD Anderson Cancer Center.

Phase 2 CAR-T study reports significant remission rates at 15-month follow up

(University of Texas M. D. Anderson Cancer Center) A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment with axi-cel (marketed as Yescarta?).

PARP Inhibitor Improves Progression-Free Survival in Patients with Advanced Breast Cancers and BRCA Mutations

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA

(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase III trial led by researchers at the University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) andShow More Summary

Novel Regulation of Gene Expression in Brain Tumors Identified

Study results revealed previously unknown interplay between two key enzymes and a novel understanding of how brain cancer tumors form and spread, according to researchers at The University of Texas MD Anderson Cancer Center.

MD Anderson to present key drug study findings for multiple blood cancers at ASH annual meeting

(University of Texas M. D. Anderson Cancer Center) Researchers at The University of Texas MD Anderson Cancer Center will present their latest findings involving drug treatments for blood cancers at the American Society of Hematology's (ASH) Annual Meeting & Exposition Dec. 8-12 in Atlanta.

MD Anderson to Present Key Drug Study Findings for Multiple Blood Cancers at ASH Annual Meeting

Researchers at The University of Texas MD Anderson Cancer Center will present their latest findings involving drug treatments for blood cancers at the American Society of Hematology's (ASH) Annual Meeting & Exposition Dec. 8-12 in Atlanta.

Researchers use fluorescent carbon nanotube probes to detect ovarian cancer

Researchers at Rice University and the University of Texas MD Anderson Cancer Center have refined and, for the first time, run in vivo tests of a method that may allow nanotube-based probes to locate specific tumors in the body. Their ability to pinpoint tumors with submillimeter accuracy could eventually improve early detection and treatment of ovarian cancer.

Copyright © 2015 Regator, LLC